HCV treatment today: pegylated interferons and ribavirin
|
|
- Helen Hardy
- 8 years ago
- Views:
Transcription
1 HCV treatment today: pegylated interferons and ribavirin
2 Other special patient populations
3 Patients with cirrhosis
4 Higher SVR rates are achieved in patients without cirrhosis Patients without bridging fibrosis/cirrhosis Patients with bridging fibrosis/cirrhosis p=0.011 p= p= SVR (%) n= Genotype 1/4 48 weeks Genotype 2/3 24 weeks Genotype 2/3 16 weeks Bruno S, et al. 43rd EASL 2008; Abstract 774
5 High SVR rates with PEGASYS in cirrhotic patients who achieve an RVR or a cevr G1 patients, 48 weeks PEGASYS 180 μg/wk plus COPEGUS 1000/1200 mg/day G2/3 patients, 24 weeks PEGASYS 180 μg/wk plus COPEGUS 800 mg/day SVR (%) n= RVR cevr Bruno S, et al. 43rd EASL 2008; Abstract 774
6 Younger age and low viral load are predictive of achieving an SVR in patients with cirrhosis Genotype 1/4 patients with bridging fibrosis/cirrhosis treated with PEGASYS 180 μ g/wk plus COPEGUS 1000/1200 mg/day for 48 weeks SVR (%) n= 59 Age <40yrs Age 40yrs 67 Viral load < IU/mL 40 Viral load IU/mL Bruno S, et al. 43rd EASL 2008; Abstract 774
7 On-treatment responses are predictive of SVR in G1/4 patients with advanced fibrosis G1/4 Predictor Baseline factors Higher serum HCV RNA level (per log 10 IU/mL increment) Odds ratio (95% confidence interval) 0.36 ( ) p Baseline and on-treatment factors On-treatment response (RVR or cevr vs. pevr or no EVR) Cumulative ribavirin dose ( 60% vs. <60% of the planned dose) ( ) ( ) < Bruno S, et al. 43rd EASL 2008; Abstract 774
8 On-treatment responses are predictive of SVR in G2/3 patients with advanced fibrosis G2/3 Predictor Baseline factors Baseline and on-treatment factors Higher body weight (per 10 kg increment) Higher serum HCV RNA level (per log 10 IU/mL increment) Higher serum HCV RNA level (per log 10 IU/mL increment) On-treatment response (RVR or cevr vs. pevr or no EVR) Cumulative ribavirin dose ( 60% vs. <60% of the planned dose) Odds ratio (95% confidence interval) 0.84 ( ) 0.46 ( ) 0.67 ( ) ( ) 9.79 ( ) p < < Bruno S, et al. 43rd EASL 2008; Abstract 774
9 Chronic hepatitis C and normal alanine aminotransferase (ALT) levels
10 Chronic hepatitis C and alanine aminotransferase (ALT) Up to 46% of patients with chronic hepatitis C have ALT levels within the currently defined normal range 1 These patients were historically considered healthy or asymptomatic and have not received treatment However, >80% have some degree of liver damage on biopsy 2 Quality of life is significantly impaired in patients with chronic hepatitis C (and elevated or persistently normal ALT) 3 1. Alberti A, et al. Ann Intern Med 2002; 137: Puoti C, et al. J Hepatol 2002; 37: Foster G, et al. Hepatology 1998; 27: 209
11 ALT levels do not always correlate with degree or severity of liver disease Although elevated ALT levels are generally associated with hepatocellular damage, lower levels are not always associated with mild liver disease ALT levels fall as cirrhosis develops Many factors, independent of liver damage, can affect ALT levels ALT levels may fluctuate throughout the course of chronic hepatitis C
12 A single ALT value may not be representative of the true ALT status It is recommended that ALT status be defined by three measurements over a 6-month period 1 However, studies suggest that this time period may not be adequate 2 Patients with ALT levels within the normal range may show further reduction in serum ALT levels following treatment 3 1. Marcellin P, et al. Hepatology 1997; 26: 133S 2. Puoti C, et al. J Hepatol 2002; 37: Di Bisceglie A, et al. Hepatology. 2001; 33: 704
13 77% of patients with normal ALT have some degree of liver damage Portal 26% Bridging 6% Cirrhosis 6% Portal 24% Bridging 16% Cirrhosis 22% No Fibrosis 23% Mild 39% No Fibrosis 19% Mild 19% Normal ALT Elevated ALT Shiffman M, et al. J Infect Dis 2000; 182: 1595
14 Fibrosis progression occurs in patients with normal ALT Cumulative probability of fibrosis (%) p=0.06 Elevated ALT Normal ALT Years Hui C-K, et al. J Hepatol 2003; 38: 511
15 Management of asymptomatic HCV patients with persistently normal ALT is evolving Event 1997 NIH Consensus Conference 2002 NIH Consensus Conference 2004 AASLD Practical Guidelines Recommendation Recommended not treating patients with normal ALT outside of controlled clinical trials Recommended that numerous factors (viral and host-specific) be considered when deciding whether to treat and that ALT levels should not be the only criterion Regardless of the serum ALT levels, the decision to initiate therapy should be individualised based on the severity of liver disease by liver biopsy, the potential of serious side effects, the likelihood of response, and the presence of comorbid conditions 1. NIH Consensus Statement NIH Consensus Statement. Hepatology 2002; 36: S3 3. Strader D, et al. Hepatology 2004; 39: 1147
16 PEGASYS plus COPEGUS in patients with normal ALT levels In chronic hepatitis C patients with elevated ALT levels PEGASYS plus COPEGUS therapy shows significant improvement in efficacy and tolerability over conventional interferon-based therapy across all HCV genotypes, irrespective of viral load 1 PEGASYS is the first and only pegylated interferon approved in the European Union for the treatment of patients with ALT levels persistently within the current normal range 1. Fried M, et al. N Engl J Med 2002; 347: 975
17 Zeuzem study: design 440 patients with normal ALT* randomised (3:3:1) PEGASYS plus COPEGUS ** Follow-up PEGASYS plus COPEGUS ** Untreated Study weeks *As determined on three occasions within 6 18 months before baseline **PEGASYS 180 μg/wk; COPEGUS 800 mg/day Zeuzem S, et al. Gastroenterology 2004; 127: 1724
18 PEGASYS plus COPEGUS for 48 weeks is optimal in genotype 1 SVR (%) No untreated patient cleared the virus p< % 13% 10 0 n=144 PEGASYS plus COPEGUS 24 weeks n=141 PEGASYS plus COPEGUS 48 weeks *Intent-to-treat analysis Zeuzem S, et al. Gastroenterology 2004; 127: 1724
19 PEGASYS plus COPEGUS for 24 weeks is optimal in genotype 2/ No untreated patient cleared the virus P= % 72% SVR (%) n=58 PEGASYS plus COPEGUS 24 weeks n=59 PEGASYS plus COPEGUS 48 weeks *Intent-to-treat analysis Zeuzem S, et al. Gastroenterology 2004; 127: 1724
20 No treatment-related ALT flares reported Serum ALT activity (U/L) 24 weeks 36 Patients with an SVR 32 Virological nonresponders Virological relapsers Treatment Follow-up weeks Patients with an SVR Virological nonresponders Virological relapsers Treatment Follow-up Study week Study week indicates the end of treatment Zeuzem S, et al. Gastroenterology 2004; 127: 1724
21 Adverse events in different treatment arms Adverse event (%) PEGASYS 180 μg/wk + COPEGUS 800 mg/day 24 weeks 48 weeks Untreated arm Fatigue Headache Pyrexia Myalgia Insomnia Nausea Depression Zeuzem S, et al. Gastroenterology 2004; 127: 1724
22 Proposed normal ALT treatment algorithm Treat without biopsy Liver biopsy to decide therapy No biopsy / no therapy Follow-up Genotype 2/3 and <45 50 years and highly motivated and no contraindication Genotype 1/4 or years or some contraindication or patient wants to know Genotype 1/4 with HVL and long duration of infection or age >65 years or major contraindication Treat with PEGASYS plus COPEGUS for 24 weeks F2 F0 F1 Avoid alcohol, hepatotoxins, obesity, liver steatosis Treat with Monitor PEGASYS plus COPEGUS for 48 weeks according to genotype Monitor every 6 months Alberti A, et al. J Hepatol 2005; 42: 266
23 HRQL improved in normal ALT responders to PEGASYS plus COPEGUS Adjusted HRQL scores ** 77 SVR No SVR 81 ** ** * 69 0 Pain Index HRQL = health-related quality of life ** p<0.0001; * p<0.05 Higher score indicates better HRQL Vitality Social functioning SF-36 scores General Health Role Physical Arora, S et al. J Gastroenterol Hepatol 2006; 21: 406
24 PEGASYS plus COPEGUS improves health-related quality of life (HRQL) SVR in response to PEGASYS, alone or in combination with COPEGUS, is associated with improved HRQL and less fatigue in patients with chronic hepatitis C and elevated ALT levels 1,2 HRQL was significantly improved in patients with persistently normal ALT who achieved an SVR in response to PEGASYS plus COPEGUS 3 1. Bernstein D, et al. Hepatology 2002; 35: Hassanein T, et al. J Hepatol 2004; 40: Arora S, et al. J Gastroenterol Hepatol 2006; 21: 406
25 PEGASYS plus COPEGUS is cost-effective in patients with normal ALT Genotype 1 PEGASYS plus COPEGUS for 48 weeks No treatment Difference Probability of cirrhosis 19% 32% 13% Life-years Quality-adjusted life years Costs (Euros) PEGASYS plus COPEGUS Other medical costs Cost-effectiveness (Euros) Per life year gained Per quality-adjusted life year gained Hornberger J, et al. J Viral Hepat 2006; 13: 377
26 Normal ALT: conclusions (I) Patients with chronic hepatitis C and persistently normal ALT can have progressive disease PEGASYS plus COPEGUS combination therapy is effective and safe in patients with elevated or persistently normal ALT levels As in patients with elevated ALT, the optimal treatment duration in patients with normal ALT is 24 weeks for genotypes 2 or 3 and 48 weeks for genotype 1
27 Normal ALT: conclusions (II) SVR following PEGASYS plus COPEGUS combination therapy has a positive impact on HRQL in patients with chronic hepatitis C, regardless of ALT levels PEGASYS plus COPEGUS is projected to reduce the incidence of cirrhosis, increase life expectancy, and have an acceptable cost-effectiveness ratio from a societal perspective in patients with normal ALT HRQL = health-related quality of life
28 Treatment and ALT levels Regardless of serum aminotransferase levels, the decision to initiate therapy with interferon and ribavirin should be individualized based on the severity of liver disease by liver biopsy, the potential of serious side effects, the likelihood of response, and the presence of comorbid conditions Strader D, et al. Hepatology 2004; 39: 1147
29 Genotype 4
30 Background Infection with HCV genotype 4 has been historically termed difficult-to-cure due to poor response to conventional IFN-based therapy 1 PEGASYS monotherapy achieves a sustained virological response rate of 45% 2 1. Zylberberg H, et al. Ann Intern Med 2000; 132: Sherman M, et al. Ann Intern Med 2001; 135: 927
31 PEGASYS plus COPEGUS in genotype 4: study objectives To retrospectively study the efficacy and safety of 24 or 48 weeks of treatment with PEGASYS combined with an 800 or mg daily dose of COPEGUS To determine an optimal treatment regimen in chronic hepatitis C patients infected with HCV genotype 4 Diago M, et al. Ann Intern Med 2004; 140: 72
32 PEGASYS 180 μg/wk plus COPEGUS mg/day for 48 weeks is optimal PEGASYS 180 μg plus COPEGUS LD SVR (%) % 63% 79% 24-SD 48-LD 48-SD 20 0% 0 Intent-to-treat analysis. Retrospective analysis of two phase III trials n= LD = RBV 800 mg/day SD = RBV mg/day Diago M, et al. Ann Intern Med 2004; 140: 72
33 Genotype 4: conclusions For patients with HCV genotype 4, both treatment duration and COPEGUS dose affect treatment outcome The optimal treatment regimen is PEGASYS 180 μg/wk plus COPEGUS mg/day for 48 weeks 1 A treatment duration of 24 weeks may now be considered for genotype 4 patients who achieve an RVR (EU only) 2 Using this regimen it is possible to achieve the high SVRs reported for genotypes 2 and Diago M, et al. Ann Intern Med 2004; 140: PEGASYS Summary of Product Characteristics, revised Hadziyannis S, et al. Ann Intern Med 2004; 140: 346
34 African Americans
35 HCV infection and African Americans Antibody to HCV is twice as common 1 Higher prevalence of HCV genotype 1 2 Poor response rate to interferon alfa 2 1. Armstrong G, et al. Ann Intern Med 2006; 144: McHutchison J, et al. Gastroenterology 2000; 119: 1327
36 African Americans have a poor response to IFN-based therapy IFNα-2b for 48 weeks IFNα-2b + RBV for 48 weeks 42% 43% Responders (%) % 16% 17% 10 8% 0 0% African American (n=26) 0% Hispanic (n=17) Caucasian (n=929) Asian (n=13) McHutchison J, et al. Gastroenterology 2000; 119: 1327
37 Higher SVR rates with PEGASYS plus COPEGUS in African Americans Genotype 1; 48-week treatment duration in African Americans Peg-IFNα-2b (12KD) + RBV PEGASYS + COPEGUS SVR (%) % % 28% 26% 31% n= McHutchison 1 0 n= Jeffers 2 Conjeevaram McHutchison Hoofnagle 4 1. McHutchison JG, et al. N Engl J Med 2009: 361: Jeffers M, et al. Hepatology 2004;39: Conjeevaram H, et al. Gastroenterology 2006; 131: Hoofnagle JH, et al. JID 2009; 199: 1112
38 High SVR rates with PEGASYS plus COPEGUS in African American patients with rapid and early virological responses Genotype 1; 48-week PEGASYS + COPEGUS treatment duration African Americans Non-African Americans SVR (%) n= 92% 77% Undetectable at week 2 or 4 60% 72% Undetectable at week McCone J, et al 59th AASLD Abstract 268: oral
39 Adherence to >60% PEGASYS plus COPEGUS improves SVR in AAs* Cumulative exposure to PEGASYS + COPEGUS 40 >80% 30 29% 30% >60% 80% SVR (%) 20 60% Genotype % 0 0% n= *AAs = African Americans Howell C, et al. J Viral Hepat 2006; 13: 371
40 Significant increase in SVR rates with decreasing fibrosis score in genotype Fibrosis score: SVR (%) PEGASYS 180 μg plus COPEGUS African Americans p= % 25% 25% 20% 0 1 or 2 3 or 4 5 or 6 Caucasian Americans 68% p= % 50% 26% 0 1 or 2 3 or 4 5 or 6 n= Conjeevaram H, et al. 56th AASLD 2005; Abstract 199
41 PEGASYS plus COPEGUS is effective in African Americans SVR of 31% in African Americans with genotype 1 is the highest response seen so far in this patient population Conjeevaram H, et al. Gastroenterology 2006; 131: 470
42 Asians
43 PEGASYS plus COPEGUS in Japanese patients with HCV genotype 1 Treatment naive, genotype 1b n=200 PEGASYS 180 µg/week plus COPEGUS mg/day PEGASYS 180 µg/week Follow-up Follow-up Study week Sakai T, et al. 41st EASL 2006; Abstract 605
44 PEGASYS plus COPEGUS provides highest SVR seen in Japanese genotype 1 patients p<0.001 SVR (%) % 61% 20 0 n= 101 PEGASYS monotherapy 99 PEGASYS plus COPEGUS Sakai T, et al. 41st EASL 2006; Abstract 605
45 PEGASYS plus COPEGUS in Taiwanese patients with HCV genotype 2 Treatment naive, genotype 2 n=150 n=50 n=100 PEGASYS 180 µg/wk plus COPEGUS mg/day PEGASYS 180 µg/wk plus COPEGUS mg/day Follow-up Follow-up Study weeks Yu M-L, et al. Gut 2006, in press Randomisation (1:2) Yu M-L, et al. Gut 2007: 56: 553
46 Abbreviated treatment is as effective as standard treatment in Taiwanese patients achieving an RVR 100% SVR PEGASYS 180 μg plus COPEGUS 80% RVR: YES 87% (130 / 150) 60% 40% 98% 100% 16 weeks 24 weeks 20% All patients (n=150) 0% 100% SVR 80% RVR: NO 13% (20 / 150) 60% 40% 20% 57% 77% 16 weeks 24 weeks RVR: HCV RNA <50 IU/mL at week 4 0% Yu M-L, et al. Gut 2007: 56: 553
47 Patients of Latino origin
48 PEGASYS plus COPEGUS in Latino and non- Latino white patients with HCV G1 infection: study design Multicenter, open-label, non-randomised, prospective study N=569* Latinos: n= 269 Non-Latinos: n=300 Treatment naive, CHC, HCV G1 PEGASYS 180 µg/week plus COPEGUS 1000/1200 mg/day Follow-up Study weeks *All treated patients CHC: chronic hepatitis C infection; HCV G1: hepatitis C genotype 1 Rodriguez-Torres M, et al. N Engl J Med 2009; 360:
49 The Latino study: Baseline characteristics Characteristic * Latino (n=269) Non-Latino (n=300) Males n (%) 183 (68) 192 (64) Age, Mean (years) 45.6± ±8.3 Weight, Mean (kg) 83.2± ±19.0 BMI, Mean >27, n (%) 29.7± (65) 27.9± (51) HCV RNA, IU/mL Mean log ± ±0.8 HCV RNA >400,000 IU/mL, n (%) 229 (85) 254 (85) ALT quotient, Mean 2.2± ±1.8 >3, n(%) 66 (25) 50 (17) Cirrhosis n (%) 36 (13) 29 (10) *All treated patients; plus/minus values are means ±SD. BMI: body-mass index; ALT: alanine aminotransferase. Baseline ALT quotient = ALT/upper limit of normal. Rodriguez-Torres M, et al. N Engl J Med 2009; 360:
50 MLR analysis: Non-Latino ethnic background is a strong predictor of SVR Multiple logistic regression Ethnic group (non-latino vs. Latino) Baseline HCV RNA level ( 400,000 vs. >400,000 IU/mL) Baseline ALT quotient* ( 3 vs. >3) Cirrhosis (no vs. yes) BMI (>27 vs. 27) OR for SVR (95% CI) p-value <0.001 < Worse *ALT quotient = ALT/upper limit of normal. HCV: hepatitis C virus; BMI: body-mass index; OR: odds ratio; CI: confidence interval. Better Rodriguez-Torres M, et al. N Engl J Med 2009; 360:
51 More than one-third of Latino patients infected with HCV G1 achieved an SVR Latinos Non-Latinos 100 p<0.001 p<0.001 p<0.001 Patients with virologic response (%) p= p< Virological response: undetectable serum hepatitis C virus (HCV) RNA level (<28 IU/mL). EOT: end-of-treatment; SVR: sustained virological response Study Week EOT SVR Rodriguez-Torres M, et al. N Engl J Med 2009; 360:
52 Transplant recipients
53 Recurrent hepatitis C in liver transplant (LT) recipients After LT, HCV recurrence is almost universal, with ~10 to 30% of patients developing cirrhosis within 5 years 1,2 Treatment of HCV recurrence after LT is difficult and results are disappointing: 3,4 SVR with combination therapy had been achieved in 21 45% of the cases The risk of treatment-induced rejection ranges from 4 25% Tolerance is poor: 20 43% of patients discontinue treatment 1. Gane E, et al. N Engl J Med 1996; 334: Sanchez-Fueyo A, et al. Transplantation 2002; 73: Samuel D, et al. Gastroenterology 2003; 124: Dumortier J, et al. J Hepatol 2004; 40: 669
54 PEGASYS monotherapy for treatment and prophylaxis of recurrent HCV infection SVR (%) Patients had undergone orthoptic liver transplantation (OLT) % PEGASYS 180 μg/wk monotherapy Prophylaxis 0% Untreated control 12%* PEGASYS 180 μg/wk monotherapy Treatment 0% Untreated control *p=0.03 vs control Chalasani N, et al. Hepatology 2005; 41: 289
55 PEGASYS plus COPEGUS in LT patients with recurrent HCV infection Objectives To test for the efficacy of a 1-year combination therapy with PEGASYS plus COPEGUS in LT patients with established recurrent HCV infection To investigate whether a 1-year maintenance therapy with COPEGUS following a 1-year combination therapy had a positive impact on post-lt HCV recurrence Duvoux C, et al. 41st EASL 2006; Abstract 1
56 Duvoux et al. study design Liver biopsy Liver biopsy Liver biopsy COPEGUS Follow-up PEGASYS plus COPEGUS Stratified by HCV RNA Placebo Follow-up Months End of combination therapy Randomisation Duvoux C, et al. 41st EASL 2006; Abstract 1
57 Excellent virological response following 12 months of PEGASYS plus COPEGUS 80 75% Virological response (%) % 0 60/97 62/83 Intent-to-treat Per protocol 14 patients withdrawn before 12 months Duvoux C, et al. 41st EASL 2006; Abstract 1
58 Keeping in mind the frequent use of growth factors, tolerability was good 22 serious adverse events related to antiviral therapy occurred in 18 patients 2 reversible rejection episodes (2%) Treatment was discontinued in 12 patients, due to serious adverse events: Haematological reasons (n=7) anaemia 6, leucopenia 1 Psychiatric reasons (n=2) Impairment in renal function (n=2) Rejection (n=1) Duvoux C, et al. 41st EASL 2006; Abstract 1
59 Prophylaxis of HCV post-olt: PHOENIX study Post-OLT, n= PEGASYS µg/wk 180 µg/wk plus COPEGUS mg/day (escalated) No treatment Follow-up Follow-up Randomisation 1:1
60 PEGASYS in transplant recipients: conclusion PEGASYS plus COPEGUS combination therapy has shown encouraging results in the treatment of recurrent HCV infection following LT Prophylaxis with PEGASYS monotherapy improves outcomes in patients with recurrent HCV infection following OLT The efficacy of PEGASYS plus COPEGUS combination therapy for the prophylaxis of recurrent HCV infection following OLT is currently being investigated in the PHOENIX trial 1. Duvoux C, et al. 41st EASL 2006; Abstract 1 2. Chalasani N, et al. Hepatology 2005; 41: 289
61 Patients with renal impairment
62 HCV in patients with renal impairment HCV is a significant cause of liver disease leading to morbidity/mortality in HCV-infected end-stage renal disease (ESRD) patients 1 HCV-infected ESRD patients show increased mortality on haemodialysis 2 and increased risk of mortality and graft loss after transplantation 3 Eradication of HCV can increase eligibility for kidney transplantation and improve outcomes 4,5 1. Pereira BJG, et al. Kidney Int 1998; 53: Butt AA, et al. J Viral Hepat 2007; 14: Fabrizi F, et al. Am J Transplant 2005; 5: Martin P, Fabrizi F, et al. J Hepatol 2008; 49: Kamar N, et al. Transplantation 2006; 82: 853
63 Prevalence of HCV in end-stage renal disease patients Higher prevalence of HCV infection in ESRD patients compared with the general population 1,2 HCV infects about 10% of ESRD patients undergoing haemodialysis in the US 2 Higher prevalence in developing countries 2 Infection of dialysis patients via nosocomial transmission 2 1. Dienstag JL, McHutchison JG, Gastroenterology 2006; 130: Fabrizi F, et al. Hepatology 2002; 36: 3
64 HCV treatment in end-stage renal disease ESRD patients have impaired drug absorption, distribution, metabolism and clearance leading to: Increase in adverse events 1 High discontinuation rates 1 Interferon-based therapies may require dose adjustment due to alterations in clearance 1 Reducing doses of peginterferon and/or RBV may allow safe treatment of ESRD patients on dialysis 2 4 RBV should not be administered to patients with creatinine clearance <50 ml/min 5 1. Fabrizi F, et al. Hepatology 2002; 36: 3 2. Rendina M, et al. J Hepatol 2007, 46: Bruchfeld A, et al. J Viral Hepat 2006; 13: Sikole A et al. Renal Failure 2007; 29: COPEGUS SPC
65 PEGASYS can be safely administered in patients with renal impairment Mean PEGASYS concentration (ng/ml) *Shaded area denotes concentration of PEGASYS in subjects with normal renal function for both doses PEGASYS 135 μg/week (n=6) PEGASYS 180 μg/week (n=6) Time (hours) Single dose Lamb M, et al. Hepatology 2001; 34: 326A
66 HELPS (Haemodialysis patients: Efficacy with Low-dose PEGASYS ) Multinational, randomised, open-label clinical study Primary endpoint: SVR Patients (N=85): non-cirrhotic, interferon naive, ESRD, CHC PEGASYS 135 µg/week PEGASYS 90 µg/week Follow-up Follow-up 6 weeks screening Study weeks Randomisation (stratified by country and HCV genotype [1 vs. non-1]) Peck-Radosavljevic M, et al. 43rd EASL 2008; Abstract 999
67 HELPS: SVR rates achieved with PEGASYS in ESRD patients 100 PEGASYS 135 µg/week PEGASYS 90 µg/week 80 SVR (%) p= % 35% 61% 57% 31% 38% 20 0 All patients Patients with BL HCV RNA < IU/mL G1 patients Peck-Radosavljevic M, et al. 43rd EASL 2008; Abstract 999
68 HELPS: week 12 response with PEGASYS 135 µg/week highly predictive for SVR PEGASYS 135 µg/week (n=38) <50 IU/mL at week 12: YES 61% (23/38) 100% 80% 60% 40% 20% 0% 100% 61 14/23 SVR 39 9/23 No SVR 92 PPV: 61% <50 IU/mL at week 12: NO 32% (12/38) PPV: positive predictive value NPV: negative predictive value 80% 60% 40% 20% 0% 8 1/12 SVR 11/12 No SVR NPV: 92% Peck-Radosavljevic M, et al. 43rd EASL 2008; Abstract 999
69 HELPS: week 12 response with PEGASYS 90 µg/week highly predictive for SVR PEGASYS 90 µg/week (n=43) <50 IU/mL at week 12: YES 37% (16/43) 100% 80% 60% 40% 20% 0% 100% 98 14/16 SVR 12 2/16 No SVR 96 PPV: 88% <50 IU/mL at week 12: NO 63% (27/43) 80% 60% 40% 20% 0% 4 1/27 26/27 SVR No SVR NPV: 96% PPV: positive predictive value NPV: negative predictive value Peck-Radosavljevic M, et al. 43rd EASL 2008; Abstract 999
70 HELPS: safety and tolerability 135 μg/week (n=38) n (%) PEGASYS 90 μg/week (n=43) n (%) Patients with 1 serious AEs 14 (36.8) 14 (32.6) Withdrawal for safety reasons AEs/intercurrent illness Death Dose modifications for AEs or lab abnormalities AE Laboratory abnormality Neutropenia Thrombocytopenia 5 (13.2) 1 (2.6) 4 (10.5) 10 (26.3) 9 (23.7) 3 (7.9) 0 3 (7.9 ) 3 (7.0) 3 (7.0) 0 12 (27.9) 9 (20.9) 4 (9.3) 2 (4.7) 3 (7.0) Laboratory abnormalities Haemoglobin <8.5 g/dl Neutrophils 0.5 <0.75 x 10 9 /L Platelets 20 <50 x 10 9 /L Median cumulative dose administered, µg/kg (range) 10 (26.3) 1 (2.6) 4 (10.5) (13 144) 9 (20.9) 4 (9.3) 2 (4.7) 59 (22 123) Peck-Radosavljevic M, et al. 43rd EASL 2008; Abstract 999
71 Pharmacokinetics (PK) of RBV in CHC patients with renal impairment Renal excretion is a major elimination route of RBV and patients with renal impairment are at risk of RBV toxicity RBV is not recommended in CHC patients with creatinine clearance <50 ml/min 1 A study by Wang et al. examined the multiple-dose PK of RBV in CHC patients with renal impairment 2 Secondary objectives of the study included the evaluation of safety and tolerability of RBV and PEGASYS combination therapy in these patients 1. COPEGUS SPC 2. Wang K, et al. 59th AASLD 2008; Abstract 1864
72 Pharmacokinetics (PK) of RBV in CHC patients with renal impairment: study design Screening Day -35 to -1 PK and safety assessments Weeks 1 12 Treatment extension and safety assessments Additional 12 or 36 weeks* Follow-up Patients (N=63) CHC, Renal impairment A B C D Moderate renal impairment PEGASYS 180 µg/week plus ribavirin 600 mg daily Severe renal impairment PEGASYS 180 µg/week plus ribavirin 400 mg daily End-stage renal disease PEGASYS 135 µg/week plus ribavirin 200 mg daily Normal renal function PEGASYS 180 µg/week plus ribavirin* Within 1 week of completion or d/c of treatment Study weeks *G2/G3 patients received a total of 24 weeks treatment plus 800 mg RBV G1/G4 patients received a total of 48 weeks treatment plus 1000/1200 mg RBV Wang K, et al. 59th AASLD 2008; Abstract 1864
73 Lowest multiple-dose exposure of RBV at week 12 in patients with ESRD RBV AUC 0-12 * (ng h/ml) Individual patient value Mean Median 0 A (n=9) B (n=9) C (n=12) D (n=12) * AUC 0-12 : area under the plasma concentration-time curve A, Moderate renal impairment; B, Severe renal impairment; C, End-stage renal disease; D, Normal renal function Wang K, et al. 59th AASLD 2008; Abstract 1864
74 Lower apparent clearance of RBV at week 12 in patients with impaired renal function RBV CL/F* (L/h) Individual patient value Mean Median A (n=9) B (n=8) C (n=7) D (n=12) * CL/F: apparent total body clearance A, Moderate renal impairment; B, Severe renal impairment; C, End-stage renal disease; D, Normal renal function Wang K, et al. 59th AASLD 2008; Abstract 1864
75 Wang study: safety Treatment group Group A (n=17) Group B (n=14) Group C (n=18) Group D (n=13) Any AE, n (%) 17 (100) 14 (100) 17 (94) 13 (100) Related AE* 17 (100) 14 (100) 17 (94) 13 (100) Serious AEs, n (%) 4 (24) 5 (36) 7 (39) 1 (8) Related serious AEs* 1 (6) 3 (21) 3 (17) 0 (0) Deaths, n (%) 0 (0) 1 (7) 1 (6) 0 (0) Premature discontinuations for AEs or lab abnormalities, n (%) RBV 4 (24) 8 (57) 3 (17) 0 (0) PEGASYS 0 (0) 5 (36) 3 (17) 0 (0) *Judged by the investigator A, Moderate renal impairment; B, Severe renal impairment; C, End-stage renal disease; D, Normal renal function Wang K, et al. 59th AASLD 2008; Abstract 1864
76 Patients with ESRD treated with 200 mg/day RBV are able to maintain exposure Treatment group Daily RBV dose (mg) Time treated with assigned dose of RBV* A (n=17) 600 B (n=14) 400 C (n=19) 200 D (n=13) 1000 or 1200 According to genotype 40% of study duration, n (%) 3 (30) 2 (50) 9 (100) 9 (100) 60% of study duration, n (%) 2 (20) 1 (25) 9 (100) 9 (100) 80% of study duration, n (%) 1 (10) 0 (0) 8 (89) 9 (100) *Evaluated in 10 patients of Group A, four patients of Group B, nine patients of Group C, and nine patients of Group D who received 80% of assigned dose of PEGASYS. Maximum study duration was 168 days for HCV genotype 2- or 3-infected patients and 336 days for HCV genotype 1- or 4-infected patients. A, Moderate renal impairment; B, Severe renal impairment; C, End-stage renal disease; D, Normal renal function Wang K, et al. 59th AASLD 2008; Abstract 1864
77 Patients with renal impairment: conclusions CHC patients with ESRD can achieve an SVR with PEGASYS A week 12 response is highly predictive of SVR in ESRD patients PEGASYS doses of 135 and 90 μg/week were well-tolerated and showed similar safety profiles PEGASYS 135 µg/week plus daily RBV 200 mg/day was well-tolerated among patients with ESRD Adherence to therapy was similar between patients with ESRD and patients with normal renal function
78 Children and adolescents
79 Chronic hepatitis C in children and adolescents The prevalence of HCV in children is approximately: 0.2% in those younger than 12 years old 1 0.4% in those between 12 and 19 years old 1 The main route of transmission of HCV in children is blood transfusion 2 Of those infected, 30-60% will develop chronic HCV infection 1 Children with HCV respond better to IFN than adults: Sustained response rates in patients with HCV genotype 1 infection: 27% vs. 8 10% for children and adults respectively 3 1. Mushtaq M et al. Curr Pediatr Res 2009; 13 (1 & 2): El-Raziky MS et al. World J Gastroenterol 2007; 13(12): Jacobson IM et al. J Pediatr Gastroenterol Nutr Jan; 34(1): 52
80 CHIPS study: PEGASYS plus COPEGUS in children and teenagers with chronic HCV infection PEGASYS 100 µg/m 2 /wk plus COPEGUS 15 mg/kg/day Treatment naive, HCV - infected children, ages 6 18 (n=65) Group A Group B Genotype 2/3 Genotype 1/4/5/6 Follow-up Follow-up Study weeks Design: Prospective, open-label, multicentre, pilot study CHIPS=Chronic Hepatitis C International Paediatric Study PEGASYS SPC 2009
81 PEGASYS plus COPEGUS in children and adolescents Efficacy results were similar to those reported in adults Preliminary data demonstrated no obvious departure from the known safety profile of the combination in adults with chronic HCV infection PEGASYS SPC 2009
82 PEDS-C study: assessing safety and efficacy of PEGASYS plus COPEGUS in children and adolescents with chronic HCV infection Treatment-naive, (HCV -infected children, ages 5-17 (n=114) PEGASYS 180 µg/1.73 m 2 /week plus COPEGUS 15 mg/kg/d PEGASYS 180 µg/1.73 m 2 /week plus placebo Follow-up Follow-up 0 24 Study weeks Design: US multicentre, randomised, placebo-controlled trial Randomisation Schwarz KB, et al. 59th AASLD 2008: Abstract 242
83 PEDS-C study: higher SVR rates with PEGASYS plus COPEGUS PEGASYS 180 µg/1.73 m 2 /week plus RBV 15 mg/kg/d PEGASYS 180 µg/1.73 m 2 /week plus placebo 100 p<0.001 p=0.003 p= SVR (%) Overall Genotype 1 Genotype 2/3 Schwarz KB, et al. 59th AASLD 2008: Abstract 242
84 PEDS-C study: lower relapse rates with PEGASYS plus COPEGUS PEGASYS 180 µg/1.73 m 2 /week plus RBV 15 mg/kg/d PEGASYS 180 µg/1.73 m 2 /week plus placebo Relapse rate (%) /35 10/22 Schwarz KB, et al. 59th AASLD 2008: Abstract 242
85 PEDS-C study: similar rates of adverse events with mono and combination therapy Adverse events related to therapy (%) Flu PEGASYS 180 µg/1.73 m 2 /week plus RBV 15 mg/kg/d PEGASYS 180 µg/1.73 m 2 /week plus placebo Headache GI symptoms Injection site rx Joint aches Irritability Rash Anorexia Depression Schwarz KB, et al. 59th AASLD 2008: Abstract 242
86 PEDS-C Study: conclusions Higher SVR rates achieved with PEGASYS plus COPEGUS compared with PEGASYS monotherapy SVR rates in children and adolescents treated with PEGASYS plus COPEGUS are similar to those reported in adult patients PEGASYS plus COPEGUS was generally well tolerated in children and adolescents Side effects were similar to those observed in adult patients Schwarz KB, et al. 59th AASLD 2008: Abstract 242
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationHCV Treatment Failure
بسم االله الرحمن الرحيم HCV Treatment Failure Gamal Esmat PROF.OF HEPATOLOGY&TROPICAL MEDICINE CAIRO UNIVERSITY Director of Viral Hepatitis Treatment Centers (VHTCs( VHTCs) MOH-EGYPT www.gamalesmat.com
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationScottish Medicines Consortium
Scottish Medicines Consortium peginterferon alfa-2a, 135 microgram/ml and 180 microgram/ml pre-filled injections of solution for subcutaneous injection (Pegasys ) No. (561/09) Roche Products Limited 10
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationHepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationUpdate on hepatitis C: treatment and care and future directions
Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New
More informationMonitoring of Treatment of viral hepatitis C
Monitoring of Treatment of viral hepatitis C J.Boubaker Department of Gastroenterology La Rabta hospital Tunis-Tunisia Monitoring of Hepatitis C Treatment Aims of Monitoring : Evaluate Efficacy. Detect
More informationLong-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationPost AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in
Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull
More informationSCIENTIFIC DISCUSSION
London, 13 October 2005 Product name: PEGINTRON Procedure No. EMEA/H/C/280/II/54 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationRibavirin/Pegylated Interferon Combination Therapy for People with Hepatitis C
Ribavirin/Pegylated Combination Therapy for People with Hepatitis C 1. Introduction 2. What the treatment does 3. When to take it 4. What is? 5. What is interferon? 6. What is pegylated interferon? 7.
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationHCV Case Study. Optimizing Outcomes with Current Therapies
HCV Case Study Optimizing Outcomes with Current Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationDebate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities
Debate: To Treat Now or Not to Treat Now Age, Disease Stage, Resistance, and Comorbidities Moderator: Raymond T. Chung, MD Associate Professor of Medicine, Harvard Medical School Director of Hepatology
More informationTreatment of Hepatitis C in Patients with Renal Insufficiency
HEPATITIS WEB STUDY HEPATITIS C ONLINE Treatment of Hepatitis C in Patients with Renal Insufficiency Robert G. Gish MD Professor Consultant, Stanford University Medical Center Senior Medical Director,
More informationNew treatment options for HCV: implications for the Optimal Use of HCV Assays
New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational
More informationManagement of non response or relapse following HCV therapy. Greg Dore Darrell Crawford
Management of non response or relapse following HCV therapy Greg Dore Darrell Crawford Learning objectives To understand importance of characterisation of prior HCV therapy response To explore options
More informationBoehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
More informationHepatitis C Treatment: Tailoring Therapy To Maximize Response
PRINTER-FRIENDLY VERSION AT GASTROENDONEWS.COM Hepatitis C Treatment: Tailoring Therapy To Maximize Response PATRICK J. AMAR, MD Department of Gastroenterology and Hepatology Holy Cross Medical Group Fort
More informationIntroduction. Background
INFORMATION DRIVES SOUND ANALYSIS, INSIGHT PHARMACY BENEFIT ADVISORY Introduction According to the Centers for Disease Control and Prevention (CDC), the rate of new hepatitis C virus (HCV) infections in
More informationMedical publications on HBV and HCV Coinfection
Recent advances of HBV and HCV co-infection 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28 Outline Epidemiology of HBV and HCV coinfection Clinical significance of HBV and HCV coinfection Interplay between
More informationPrior Authorization Policy
Prior Authorization Policy http://www.paramounthealthcare.com/providers Ribavirin Rebetol (ribavirin capsule or oral solution) Copegus (ribavirin tablet), Moderiba (ribavirin tablet), Ribasphere (ribavirin
More informationHepatitis Update. HCV Cure As A Paradigm for Convergence of Interests. Evidence Based Nuts and Bolts For the Family Doc 11/5/2014
Evidence Based Nuts and Bolts For the Family Doc Hepatitis Update William Carey MD MACG, FAASLD Oct 25, 2014 HCV Cure As A Paradigm for Convergence of Interests Hepatitis C Cure 1 Get Ready Get SET Go
More informationHIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Pegasys and non-preferred Hepatitis C Agents must
More informationOptimising therapy in chronic hepatitis B: Switch or add treatment
Optimising therapy in chronic hepatitis B: Switch or add treatment Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University,Thailand NA + NA Percent with resistance
More informationIn this study, the DCV+ASV regimen had low rates of discontinuation (5%) due to adverse events, and low rates of serious adverse events (5.
BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection An overall SVR 24 rate of 84.7 percent was
More informationManaging Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study
Managing Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study Case Prepared by Sinēad Sheils CNC Royal Prince Alfred Hospital, Sydney Friday 17 th May 2013 Nigel 63 yrs old caucasian male HCV
More informationNew IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationHEPATITIS C TREATMENT GUIDELINES
HEPATITIS C TREATMENT GUIDELINES Updated May 21, 2014 INSTRUCTIONS: 1. Review the posted Hepatitis C Treatment Guidelines document to validate that your patient meets the criteria for treatment. 2. Complete
More informationHepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
More informationSafety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B
Safety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B Anna S. F. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology University
More informationRobert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
More informationAfter the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365
Ombitasvir paritaprevir ritonavir with or without dasabuvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365 NICE 2015. All rights reserved.
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationCurrent Opinion in Hepatitis C Treatment
White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University
More informationPURPOSE: To define the criteria to be used to determine the medical necessity of antiviral therapy in the treatment of Chronic Hepatitis B.
COVENTRY Health Care Guidelines for Hepatitis B Therapy SUBJECT: Chronic Hepatitis B Therapy: a. Interferons - Intron A (interferon alfa-2b) and Pegasys (peginterferon alfa-2a) b. Nucleoside analogues
More informationA 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
More informationPHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
More informationPREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
More informationSafety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
More informationIndividualizing treatment duration in hepatitis C virus genotype 2/3-infected patients
Liver International ISSN 1478-3223 REVIEW ARTICLE Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients Alessandra Mangia Liver Unit, IRCCS Hospital Casa Sollievo della
More informationIt has been estimated that approximately 25% 46% of. Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:645 652 Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels MITCHELL L. SHIFFMAN,* MOISÉS DIAGO, ALBERT TRAN, PAUL POCKROS,
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationProtease Inhibitors for Chronic Hepatitis C Infection: The New Kids on the Block, But do they have The Right Stuff for all patients?
Protease Inhibitors for Chronic Hepatitis C Infection: The New Kids on the Block, But do they have The Right Stuff for all patients? Lindsey M. Childs, PharmD, MPH PGY2 Infectious Diseases Pharmacy Resident
More informationThe question and answer session is not available after the live webinar.
1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments
More informationViral Hepatitis Prevention Board Meeting November 2013. The Netherlands: Hepatitis C treatment guidelines
Viral Hepatitis Prevention Board Meeting November 2013 The Netherlands: Hepatitis C treatment guidelines Floor Berden MD, PhD student Radboud university medical center Nijmegen, the Netherlands Conflicts
More informationHIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationLedipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis Massachusetts Medical Society, April 2014 sponsored by Gilead Sciences 23.04.2014 Marie-Luise Lauterjung 1 Zweck der Studie
More informationPRIOR AUTHORIZATION POLICY
PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus
More informationCommissioning Policy for Hepatitis C Treatments
Commissioning Policy for Hepatitis C Treatments Reference No: EMSCGP012V1 Version: 1 Ratified by: East Midlands Specialised Commissioning Group Date ratified: 05/06/09 Name of originator/author: Andrew
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationThe following should be current within the past 6 months:
EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,
More informationAcute HCV was defined as (3 out of 4 within the preceding 4 months):
Christoph Boesecke, Patrick Ingiliz, Hans-Jürgen Stellbrink, Mark Nelson, Sanjay Bhagani, Marguerite Guiguet, Marc-Antoine Valantin, Thomas Reiberger, Martin Vogel, Jürgen K. Rockstroh, and the NEAT study
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364
Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2015. All rights reserved. Contents 1 Guidance... 3 Table 1 Daclatasvir
More informationInnovazione farmacologica e farmacologia clinica
Innovazione farmacologica e farmacologia clinica Francesco Scaglione, MD, PhD Department of Medical Biotechnology and Translational Medicine School of medicine Postgradute School of clinical pharmacology
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Interferon,
More informationHCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationNEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with
More informationSponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
More informationLA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
More informationA collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Q1-2013 Conference Call - Presenting team Maris Hartmanis, CEO Charlotte
More informationdoi:10.1111/j.1365-2893.2009.01255.x
Journal of Viral Hepatitis, 2010, 17, 459 468 doi:10.1111/j.1365-2893.2009.01255.x Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients
More informationNew Research On Direct-acting Antivirals For The Treatment Of Hepatitis C
New Research On Direct-acting Antivirals For The Treatment Of Hepatitis C Highlights From EASL 214, London, U.K. This report contains highlights from a selection of abstracts and posters presented during
More informationPhase: IV. Study Period: 20 Jan. 2006-17 Sep. 2008
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCoinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Coinfezione HIV-HCV Raffaele Bruno, MD This program is supported by educational grants from Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
More informationHCV Pipeline: The Next 18 Months Michael W. Fried, MD
HCV Pipeline: The Next 18 Months Michael W. Fried, MD Professor of Medicine Director, UNC Liver Center University of North Carolina at Chapel Hill Michael W. Fried, MD Commercial Disclosures Grants/Research
More informationDaclatasvir for treating chronic hepatitis C
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Appraisal consultation document Daclatasvir for treating chronic hepatitis C The Department of Health has asked the National Institute for Health and Care
More informationFocus on Transplantation: Treatment Post-transplant for HBV and HCV
Focus on Transplantation: Treatment Post-transplant for HBV and HCV The Viral Hepatitis Congress, Frankfurt, 09. September 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische Klinik I
More informationRecurrent HCV Following Liver Transplantation
Recurrent HCV Following Liver Transplantation Russell H. Wiesner, MD Professor of Medicine Mayo Clinic College of Medicine Rochester, MN, USA ILTS Western/Eastern Perspective Hong Kong, CHINA April 5-6,
More informationClinical Application of HBs quantification
Clinical Application of HBs quantification Hepatology on the Nile 2 Advances in Liver Disease 2014, "World Expert Review» Wednesday, September 24, 2014 Pr Tarik Asselah MD, PhD; Service d Hépatologie &
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More information17/01/14. What are special patient groups? Management of hepatitis C in special patient groups. Management of hepatitis C in
Management of hepatitis C in special patient groups Minisymposium Challenges in viral hepatitis 14 Lausanne 16.1.14 B. Müllhaupt Gastroenterology and Hepatology Swiss HPB- and Transplant-Center University
More informationHepatitis C treatment update
Hepatitis C treatment update Viral Hepatitis Workshop Hepatitis Foundation and Regional Public Health December 2013 Jeffrey S Wong Hepatitis C treatment Non-A non-b hepatitis History of HCV treatment Hutt
More informationReview: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
More informationHepatitis C virus (HCV) genotype plays an important
Rapid Virological Response and Treatment Duration for Chronic Hepatitis C Genotype 1 Patients: A Randomized Trial Ming-Lung Yu, 1,3 Chia-Yen Dai, 1,3,4 Jee-Fu Huang, 4,5 Chang-Fu Chiu, 6 Yi-Hsin C. Yang,
More informationVersion History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationHepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form
Hepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form For assistance, please call 1-855-552-6028 or fax completed form to 570-271-5610. Medical documentation may be requested. This
More informationWhat does Hepatitis C mean to me as a CKD Patient?
What does Hepatitis C mean to me as a CKD Patient? Clinical Practice Guidelines for the Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in CKD Introduction Worldwide, about 170 million people
More informationHumulin (LY041001) Page 1 of 1
(LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or
More informationHepatitis C Treatment Expansion Initiative Multi-Site Conference Call. March 16, 2011
Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call March 16, 2011 Case Presentations Kansas City Free Health Clinic Carilion Clinic Didactic Session Challenges in Determining HCV Treatment
More informationDisclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
More informationTreatment Options for Hepatitis C in the Post Transplant Patient
Treatment Options for Hepatitis C in the Post Transplant Patient Caroline Rochon, MD, FACS,FRCSC Transplant and Hepatobiliary Surgery Hartford Hospital Assistant Professor of Surgery, University of Connecticut
More informationHepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015
Hepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015 Disclosures: In the past two years I have participated in research 1 or received consultation/speaking fees 2 from: Astellas 2 Abbvie
More informationHepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?
Hepatitis C David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham Substance Misuse Treatment in the West Midlands. How can we reduce harm? Birmingham October 19 th 2007 infection HCV Natural History
More informationHEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
More information